Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.58 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569113 | 0.86 | EGFR (0.53) | EGFRABCG2AURKARPS6KB1EPHB2 | |
| SCHEMBL5569470 | 0.84 | EGFR (0.58) | EGFRABCG2AURKBERBB2KDR | |
| SCHEMBL5568231 | 0.83 | EGFR (0.64) | EGFRERBB2MAPK1FBP1 | |
| SCHEMBL15070939 | 0.81 | EGFR (0.71) | EGFRABCG2EPHB2ERBB2KDR | |
| SCHEMBL5564908 | 0.80 | RET (0.59) | EGFRABCG2AURKARPS6KB1AURKB | |
| SCHEMBL5565322 | 0.80 | AURKA (0.52) | EGFRAURKARPS6KB1ERBB2KDR | |
| SCHEMBL5564578 | 0.80 | MAPT (0.55) | EGFRAURKARPS6KB1ERBB2 | |
| SCHEMBL2992623 | 0.78 | EGFR (1.00) | EGFRABCG2AURKBEPHB2ERBB2 | |
| SCHEMBL663875 | 0.78 | AURKA (1.00) | EGFRABCG2AURKARPS6KB1AURKB | |
| SCHEMBL5564595 | 0.77 | ABCG2 (0.67) | EGFRABCG2ERBB2KDRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885ABCG2 311/4885AURKA 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.